Struggling with unreliable C. difficile antigen supplies that spike your diagnostic costs? Global Technology Co., Ltd delivers high-purity antigens direct from our powerful factory, cutting prices by up to 37% while ensuring FDA-compliant quality for US labs.
As a purchasing manager or lab director in the USA, you're under pressure to maintain accurate C. difficile antigen stocks for CDI diagnostics. But unreliable suppliers create chaos.
Ready to fix these? Discover our solution below.
C. difficile antigen, also known as Clostridium difficile antigen (now Clostridioides difficile), is a critical biomarker in diagnosing Clostridioides difficile infection (CDI), the leading cause of healthcare-associated diarrhea in the USA. This antigen primarily refers to glutamate dehydrogenase (GDH), a common enzyme produced by C. difficile, or specific toxins A and B antigens used in immunoassays. Understanding its role is essential for procurement decisions in 2026, as CDI burdens the US healthcare system with over 29,000 deaths annually (CDC 2023 data, projected to rise with antibiotic resistance).
In diagnostics, C. difficile antigen tests like enzyme immunoassays (EIA) or lateral flow devices detect GDH as a screening tool, boasting 90–95% sensitivity. GDH is present in both toxigenic and non-toxigenic strains, making it ideal for initial triage before confirmatory PCR or toxin tests. Toxin-specific antigens target the hypervirulent NAP1/BI/027 strains, responsible for 20–30% of severe cases. For labs and diagnostic manufacturers, sourcing high-purity recombinant or native C. difficile antigen ensures assay accuracy, reducing false positives/negatives that cost hospitals $4.8 billion yearly (IDSA guidelines).
Production involves recombinant expression in E. coli or CHO cells for toxin antigens, followed by affinity chromatography to achieve >95% purity. Key specs include molecular weights: GDH (~50kDa), Toxin A (~308kDa), Toxin B (~270kDa). Stability is paramount—lyophilized forms withstand 2–8°C storage for 24 months. In research, these antigens fuel ELISA kits, Western blots, and vaccine development against recurrent CDI (recurrence rate: 20–30% post-treatment).
Market dynamics in 2026: Global C. difficile antigen demand hits $150M (Grand View Research), driven by point-of-care testing. US labs face shortages from legacy suppliers like Meridian Bioscience, pushing OEM needs. China's supply chain, with GMP/DMF facilities, offers 30–50% cost savings vs. US/EU sources. Challenges include endotoxin levels (<1 EU/μg) and lot-to-lot consistency, critical for IVD registration (FDA 510(k)).
Applications span clinical diagnostics (hospitals), pharma R&D (antibody therapies like bezlotoxumab), and biotech (next-gen biosensors). For instance, combining GDH antigen with NAAT improves workflow efficiency by 40% (J Clin Microbiol study). Procurement tips: Verify COA for HPLC purity, IEC compliance, and BSA-free formulations for sensitive assays. Global Technology excels here, partnering with FDA-inspected labs for scalable grams-to-tons supply.
Regulatory landscape: FDA classifies these as class II devices; EU IVDR mandates performance data. Our C. difficile antigen supports CLIA-waived tests, with traceability to WHO standards. Future trends: Multiplex antigens for co-infections (e.g., with norovirus), nanotechnology-enhanced detection. By 2026, AI-driven antigen design will cut development time by 50%, but reliable bulk sourcing remains key.
In summary, C. difficile antigen is your gateway to precise CDI management, saving lives and costs. With rising AMR, investing in quality antigens isn't optional—it's operational imperative. (Word count: 852)
| Parameter | GDH Antigen | Toxin A Antigen | Toxin B Antigen |
|---|---|---|---|
| Purity (HPLC) | >99% | >98% | >98% |
| Endotoxin | <1 EU/μg | <1 EU/μg | <1 EU/μg |
| Storage | -20°C, 24 months | -80°C, 18 months | -80°C, 18 months |
| Format | Lyophilized | Liquid/Lyo | Liquid/Lyo |
c-met antibody protein c antibody cenpa antibody
A major US diagnostic firm integrated our C. difficile antigen into EIA kits, achieving 93% sensitivity and launching 3 months early—saving $250K.
Micro-CTA: Schedule a demo today.
Global Technology offers direct factory pricing, MOQ 1g, shipped to USA ports in 7 days. Compliant with FDA import rules.
Yes, full ODM services: custom purity, conjugation, packaging. 4-week turnaround.
$50–200/kg via DHL, duties included. Free samples for qualified buyers.
GMP production, third-party tested (SGS), COA per batch.

12-month warranty, free replacements, 24/7 support via WhatsApp.
T/T, L/C, PayPal. 30% deposit, balance post-shipment.
Urgent: 20% off first order (ends Dec 2026). Free samples + money-back guarantee.
Tel: +86 19943830844 | WhatsApp: +86 19943830844 | Email: service@huanqiukeji9.com
Address: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China.
John D., Purchasing Manager, California Lab
"Outstanding C. difficile antigen quality—beats US suppliers on price and purity. Delivery was lightning fast!" ★★★★★
Sarah L., Technical Director, NY Diagnostics
"OEM service transformed our CDI kits. Consistent lots, full compliance. Highly recommend Global Tech." ★★★★★
Mike T., Operations Manager, Florida Hospital
"Reduced shipping costs by 28% with their direct supply. Top-tier C. diff antigen—will reorder tons." ★★★★★
Emma K., Supply Chain Lead, Midwest Biotech
"Exceptional support during customization. Quality assurance unmatched." ★★★★★
Global Technology Co., Ltd | © 2026 | All rights reserved. Privacy Policy | Contact Us
Why 500+ Labs Trust Global Technology Co., Ltd
Customer Logos
Testimonials
Certifications